TW200611712A - Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium - Google Patents

Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium

Info

Publication number
TW200611712A
TW200611712A TW094116804A TW94116804A TW200611712A TW 200611712 A TW200611712 A TW 200611712A TW 094116804 A TW094116804 A TW 094116804A TW 94116804 A TW94116804 A TW 94116804A TW 200611712 A TW200611712 A TW 200611712A
Authority
TW
Taiwan
Prior art keywords
formulations
stability during
increased stability
during transition
vehicle
Prior art date
Application number
TW094116804A
Other languages
English (en)
Inventor
Gunjan Junnarkar
Michael A Desjardin
Kui Liu
Zeng-Ji Li
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35451371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200611712(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of TW200611712A publication Critical patent/TW200611712A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW094116804A 2004-05-25 2005-05-24 Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium TW200611712A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57466204P 2004-05-25 2004-05-25
US65022605P 2005-02-03 2005-02-03

Publications (1)

Publication Number Publication Date
TW200611712A true TW200611712A (en) 2006-04-16

Family

ID=35451371

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094116804A TW200611712A (en) 2004-05-25 2005-05-24 Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium

Country Status (17)

Country Link
US (2) US20050266087A1 (zh)
EP (1) EP1755650B8 (zh)
JP (1) JP2008500345A (zh)
KR (1) KR20070046791A (zh)
AR (1) AR049118A1 (zh)
AT (1) ATE400291T1 (zh)
AU (1) AU2005247439B2 (zh)
BR (1) BRPI0511593A (zh)
CA (1) CA2568714A1 (zh)
DE (1) DE602005008053D1 (zh)
ES (1) ES2309768T3 (zh)
IL (1) IL179279A (zh)
MX (1) MXPA06013755A (zh)
NZ (1) NZ551258A (zh)
PE (1) PE20060456A1 (zh)
TW (1) TW200611712A (zh)
WO (1) WO2005115333A2 (zh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
MY135711A (en) * 2002-06-17 2008-06-30 Alza Corp Osmotic delivery system with early zero order push power engine
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
SI2218448T1 (sl) 2002-12-13 2016-01-29 Durect Corporation Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
MXPA05010605A (es) * 2003-03-31 2005-11-23 Alza Corp Bomba osmotica con medios para disipar la presion interna.
AR043810A1 (es) * 2003-03-31 2005-08-17 Alza Corp Sistema osmotico de administracion y metodo para disminuir los tiempos de llegada al regimen de funcionamiento en los sistemas osmoticos de administracion
CN1905861A (zh) * 2003-10-31 2007-01-31 阿尔扎公司 具有自保持、快启动薄膜插塞的渗透泵
EP1694310A2 (en) * 2003-11-06 2006-08-30 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
EA201001885A1 (ru) 2004-09-17 2011-12-30 Дьюрект Корпорейшн Система контролируемой доставки
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20060263433A1 (en) * 2005-02-03 2006-11-23 Ayer Rupal A Suspension formulation of interferon
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2363112B8 (en) * 2006-08-09 2018-11-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
PT2117521E (pt) 2006-11-03 2012-09-10 Durect Corp Sistemas de administração transdérmica que compreendem bupivacaína
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US20080268270A1 (en) * 2007-04-30 2008-10-30 Wenjie Chen High impact polymer interlayers
AU2008335809A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP3685837A1 (en) 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
RU2552324C2 (ru) 2008-09-17 2015-06-10 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
CN106880596A (zh) * 2008-10-15 2017-06-23 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
WO2011007327A2 (en) 2009-07-16 2011-01-20 Koninklijke Philips Electronics N.V. Suspension for therapeutic use and device for delivering said suspension
AU2010298733B2 (en) 2009-09-28 2014-10-09 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
KR20140015266A (ko) * 2010-11-24 2014-02-06 듀렉트 코퍼레이션 생분해성 약물 전달 조성물
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
EP4090353A4 (en) 2020-01-13 2023-08-09 Durect Corporation REDUCED IMPURITY EXTENDED-RELEASE DRUG DELIVERY SYSTEMS AND METHODS
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CN117159480B (zh) * 2023-11-01 2024-03-01 江西赛基生物技术有限公司 一种重组人IFN-γ蛋白冻干小球及其制备方法和应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797492A (en) * 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4305927A (en) * 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
GB9027422D0 (en) * 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5288214A (en) * 1991-09-30 1994-02-22 Toshio Fukuda Micropump
DE4137649C2 (de) * 1991-11-15 1997-11-20 Gerhard Dingler Bauelement
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5368588A (en) * 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5639477A (en) * 1993-06-23 1997-06-17 Alza Corporation Ruminal drug delivery device
US5697975A (en) * 1994-02-09 1997-12-16 The University Of Iowa Research Foundation Human cerebral cortex neural prosthetic for tinnitus
NL9401150A (nl) * 1994-07-12 1996-02-01 Nederland Ptt Werkwijze voor het aan een ontvangzijde aanbieden van een van een zendzijde afkomstig eerste aantal videosignalen, alsmede systeem, alsmede zender, alsmede netwerk, en alsmede ontvanger.
ES2191719T3 (es) * 1994-11-10 2003-09-16 Univ Kentucky Res Found Dispositivo implantable y recargable de descarga controlada para suministrar farmacos directamente a una parte interna del cuerpo.
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6395292B2 (en) * 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6156331A (en) * 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) * 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
DK1238659T3 (da) * 1996-02-02 2005-01-24 Alza Corp Vedvarende frigivelse af et aktivt middel ved anvendelse af et implanterbart system
US5976109A (en) * 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US6331311B1 (en) * 1996-12-20 2001-12-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
ZA981610B (en) * 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
AU761577C (en) * 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
EP1041975B1 (en) * 1997-12-22 2002-09-04 Alza Corporation Rate controlling membranes for controlled drug delivery devices
AU746638B2 (en) * 1997-12-29 2002-05-02 Intarcia Therapeutics, Inc. Implanter device for subcutaneous implants
ES2217613T3 (es) * 1997-12-29 2004-11-01 Alza Corporation Sistema de liberacion osmotica con mecanismo de retencion de tapon de membrana.
CA2316886C (en) * 1997-12-30 2007-09-25 Alza Corporation Beneficial agent delivery system with membrane plug
US6248112B1 (en) * 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
CN1325301A (zh) * 1998-11-02 2001-12-05 阿尔扎有限公司 活性物质的控制释放
JP4383674B2 (ja) * 1998-12-31 2009-12-16 インターシア セラピューティクス,インコーポレイティド 空間効率のよいピストンを有する浸透圧送達システム
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US20030059376A1 (en) * 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6436091B1 (en) * 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
ES2248156T3 (es) * 1999-12-21 2006-03-16 Alza Corporation Valvula para dispositivos osmoticos.
US6283949B1 (en) * 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6840831B2 (en) * 2000-09-05 2005-01-11 Robert Katz Kickboard
CA2427194A1 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
ES2554106T3 (es) * 2001-06-21 2015-12-16 Genentech, Inc. Formulación de liberación sostenida
US7163688B2 (en) * 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
JP2006512102A (ja) * 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
MY135711A (en) * 2002-06-17 2008-06-30 Alza Corp Osmotic delivery system with early zero order push power engine
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
WO2004002565A1 (en) * 2002-06-26 2004-01-08 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
KR20050038008A (ko) * 2002-07-31 2005-04-25 알자 코포레이션 주사용 저장형 조성물 및 이의 용도
US7368126B2 (en) * 2002-11-06 2008-05-06 Guohua Chen Controlled release depot formulations
US7014636B2 (en) * 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
RU2342118C2 (ru) * 2002-12-19 2008-12-27 Алза Корпорейшн Стабильные неводные однофазные гели и композиции на их основе для доставки из имплантируемого устройства
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
AR043810A1 (es) * 2003-03-31 2005-08-17 Alza Corp Sistema osmotico de administracion y metodo para disminuir los tiempos de llegada al regimen de funcionamiento en los sistemas osmoticos de administracion
MXPA05010605A (es) * 2003-03-31 2005-11-23 Alza Corp Bomba osmotica con medios para disipar la presion interna.
US20050008661A1 (en) * 2003-03-31 2005-01-13 Fereira Pamela J. Non-aqueous single phase vehicles and formulations utilizing such vehicles
US7241457B2 (en) * 2003-09-30 2007-07-10 Alza Corporation Osmotically driven active agent delivery device providing an ascending release profile
CN1905861A (zh) * 2003-10-31 2007-01-31 阿尔扎公司 具有自保持、快启动薄膜插塞的渗透泵
EP1694310A2 (en) * 2003-11-06 2006-08-30 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20050175701A1 (en) * 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060216242A1 (en) * 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20060263433A1 (en) * 2005-02-03 2006-11-23 Ayer Rupal A Suspension formulation of interferon
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US20070027105A1 (en) * 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP2363112B8 (en) * 2006-08-09 2018-11-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
EP2157967B1 (en) * 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US8343140B2 (en) * 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Also Published As

Publication number Publication date
DE602005008053D1 (de) 2008-08-21
EP1755650B1 (en) 2008-07-09
US20050266087A1 (en) 2005-12-01
EP1755650A2 (en) 2007-02-28
KR20070046791A (ko) 2007-05-03
BRPI0511593A (pt) 2008-01-02
JP2008500345A (ja) 2008-01-10
IL179279A0 (en) 2007-03-08
ES2309768T3 (es) 2008-12-16
NZ551258A (en) 2009-07-31
WO2005115333A2 (en) 2005-12-08
IL179279A (en) 2010-06-30
EP1755650B8 (en) 2008-10-15
US20080112994A1 (en) 2008-05-15
AU2005247439A1 (en) 2005-12-08
AR049118A1 (es) 2006-06-28
MXPA06013755A (es) 2007-02-08
WO2005115333A3 (en) 2006-05-18
CA2568714A1 (en) 2005-12-08
PE20060456A1 (es) 2006-06-02
AU2005247439B2 (en) 2010-02-11
ATE400291T1 (de) 2008-07-15

Similar Documents

Publication Publication Date Title
TW200611712A (en) Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
WO2006084141A8 (en) Suspension formulation of interferon
JP2008500345A5 (zh)
WO2007033372A3 (en) Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2006042132A3 (en) Microencapsulation of cells in hydrogels using electrostatic potentials
ATE531368T1 (de) Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
BRPI0519088A2 (pt) formulaÇÕes de tacrolimo nanoparticuladas
ATE385777T1 (de) Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren
DE602004021107D1 (de) Meloxican-formulierungen in nanoteilchenform
TW200518775A (en) Pharmaceutical formulations for the prolonged release of active principle(s) and their applications, especially therapeutic applications
TW200738326A (en) Aqueous suspensions of sparingly water-soluble or water-insoluble active agents and dry powders prepared therefrom
BR0108449A (pt) Formulações de pasta aperfeiçoada
WO2006002304A3 (en) Improvements in eyewear
WO2004056338A3 (en) Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
DE602005010733D1 (de) Ophthalmische emulsion mit einem immunosuppressiven mittel
WO2007075747A3 (en) Uv-radiation protectant compositions
WO2006026057A3 (en) Short corridor progressive addition lenses with reduced unwanted astigmatism
EA200702638A1 (ru) Стабильная композиция (рецептура) с наночастицами ацетаминофена
WO2007075827A3 (en) Homogeneous paste formulations
AU2019339740A8 (en) CSF-1R antibody formulation
WO2005065456A3 (de) Wirkstoffkombinationen mit insektiziden eigenschaften
MXPA05012319A (es) Suministro de compuestos con celulas sanguineas rehidratadas.
NO20066029L (no) Formuleringer som er stabile gjennom overgang fra hydrofobisk vehikkel til hydrofilt medium
WO2005007117A3 (en) Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
WO2006013391A3 (en) Conformable structures